Fundz

Rockwell Medical, Inc.

United States · Biotechnology, Healthcare, Health Care

Rockwell Medical (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide.

Key facts

Headquarters
United States
Employees
244
Industries
Biotechnology, Healthcare, Health Care
Status
Public (RMTI)
Website
rockwellmed.com
LinkedIn
Company page

Recent activity at Rockwell Medical, Inc.

  • : SEC 8-K (7.01): On August 13, 2026, Rockwell Medical, Inc. provided a Regulation FD Disclosure by making an updated corporate presentation available. This presentation is included as Exhibit 99.1 and contains significant corporate information that stakeholders may find relevant. The filing clarifies that the information shared is not to be deemed 'filed' under the Securities Exchange Act, which mitigates certain liabilities. The event date of August 13 is crucial as it aligns closely with the filing date, emphasizing the timely release of relevant corporate information to security holders.
  • : SEC 8-K (8.01):
  • : SEC 8-K (3.01): On May 8, 2026, Rockwell Medical, Inc. received a notice from the Nasdaq Stock Market indicating that the company has failed to meet the minimum bid price requirement for continued listing on the Nasdaq Capital Market. Specifically, the company’s common stock has been below the required minimum closing bid price of $1.00 per share for the past 30 consecutive business days. If this deficiency continues, it could lead to the delisting of the company's stock from Nasdaq. This situation may require the company to evaluate its options for compliance and potential corrective actions to avoid delisting.
  • : SEC 8-K (7.01): On May 7, 2026, Rockwell Medical, Inc. updated its corporate presentation, which has been made available to the public. This presentation includes recent developments and strategic insights about the company that may be of interest to stakeholders. The information, which is furnished as Exhibit 99.1, is not intended to be included as 'filed' under the Securities Exchange Act of 1934, thus protecting the registrant from certain liabilities associated with the content. The broader implications of this update could influence investor perceptions and market activity regarding Rockwell Medical, Inc.
  • : SEC 8-K (7.01): On May 7, 2026, Rockwell Medical, Inc. made available an updated corporate presentation. The information was disclosed in accordance with Regulation FD, emphasizing the transparency of information provided to the public. The corporate presentation is available as Exhibit 99.1. This disclosure is important for stakeholders interested in the latest corporate updates and strategic directions of the company, ensuring compliance with the Securities Exchange Act.
  • : SEC 8-K (7.01): On March 26, 2026, Rockwell Medical, Inc. provided a Regulation FD disclosure by making available an updated corporate presentation. This presentation, referred to as Exhibit 99.1, is intended to communicate important corporate information to investors and stakeholders, impacting the perception of the company in the market. The filing indicates adherence to SEC guidelines, ensuring that the information disclosed is not deemed 'filed' under the Exchange Act, which limits its liability. The presentation's contents may offer insights into the company's strategic direction and financial performance, reflecting key corporate developments.
  • : SEC 8-K (7.01): On March 26, 2026, Rockwell Medical, Inc. provided an updated corporate presentation that outlines recent developments and future strategies of the company. This update is crucial for investors as it presents insights into the company’s operations and market position. The corporate presentation is included as Exhibit 99.1 to this filing. The engagement enhances transparency and communication with security holders, emphasizing the importance of strategic information sharing.
  • : SEC 8-K (8.01):
  • : SEC 8-K (5.02): On November 17, 2025, Andrea Heslin Smiley resigned from the Board of Directors of Rockwell Medical, Inc., effective immediately. Her departure was not due to any disagreements with the Company. Concurrently, the Board appointed Joseph H. Dawson to serve as a Class II director until the 2026 Annual Meeting of Stockholders, also effective immediately. Mr. Dawson, previously President, North America of Nipro Medical Corporation, will receive an annual cash retainer of $45,000 and has been granted options to purchase 25,000 shares at the company's closing stock price on November 17, 2025. These options and 25,000 restricted stock units will vest on November 17, 2026, contingent upon his continued service to the Company.
  • : SEC 8-K (5.02): On November 17, 2025, Andrea Heslin Smiley resigned from the Board of Directors of Rockwell Medical, Inc., along with all Board committees she served on, effective immediately. Her resignation was not due to any disagreements regarding the Company's operations or policies. Concurrently, the Board appointed Joseph H. Dawson as a Class II director to serve until the 2026 Annual Meeting of Stockholders and until his successor is elected and qualified, also effective immediately. Mr. Dawson will additionally serve on the Naminating and Corporate Governance Committee.

Rockwell Medical, Inc. funding history

DateRoundAmount
Jun 2022Funding Round$15.0M
Oct 2018Venture$22.0M

Leadership

  • Heather Hunter, Chief Operating Officer
  • Jesse Neri, Chief Financial Officer
  • Tim Chole, Chief Commercial Officer

Verified email and direct lines for Rockwell Medical, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Rockwell Medical, Inc. files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Rockwell Medical, Inc. in the news

Companies similar to Rockwell Medical, Inc.

About Rockwell Medical, Inc.: questions and answers

What does Rockwell Medical, Inc. do?

Rockwell Medical (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide.

Where is Rockwell Medical, Inc. headquartered?

Rockwell Medical, Inc. is headquartered in United States.

How many employees does Rockwell Medical, Inc. have?

Rockwell Medical, Inc. has about 244 employees.

Has Rockwell Medical, Inc. raised funding?

Yes. Fundz has recorded 2 funding events for Rockwell Medical, Inc.. The most recent, Funding Round of $15.0M, was in Jun 2022.

What is the latest news on Rockwell Medical, Inc.?

On Aug 13, 2026, SEC 8-K (7.01): On August 13, 2026, Rockwell Medical, Inc. provided a Regulation FD Disclosure by making an updated corporate presentation available. This presentation is included as Exhibit 99.1 and contains significant corporate information that stakeholders may find relevant. The filing clarifies

Is Rockwell Medical, Inc. a public company?

Yes. Rockwell Medical, Inc. is publicly traded under the ticker RMTI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Rockwell Medical, Inc. across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.